Association between polymorphisms in phospholipase A2 genes and the plasma triglyceride response to an n-3 PUFA supplementation: a clinical trial

Lipids in Health and Disease

Marie-Claude Vohl²  Patrick Couture²  Simone Lemieux¹  Iwona Rudkowska²  Hubert Cormier¹  Bénédicte L Tremblay¹ 

[1] Institute of Nutrition and Functional Foods (INAF), Laval University, 2440 Hochelaga Blvd, Quebec G1V 0A6, QC, Canada;CHU de Québec Research Center – Endocrinology and Nephrology, 2705 Laurier Blvd, Quebec, QC, Canada

关键词: Nutrigenetics;    Phospholipase;    Omega-3 fatty acids;    Plasma lipid levels;    Gene-diet interactions;   

Others  :  1132943
DOI  :  10.1186/s12944-015-0009-2

 received in 2014-09-16, accepted in 2015-02-05,  发布年份 2015

【 摘 要 】

Background

Fish oil-derived long-chain omega-3 (n-3) polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), reduce plasma triglyceride (TG) levels. Genetic factors such as single-nucleotide polymorphisms (SNPs) found in genes involved in metabolic pathways of n-3 PUFA could be responsible for well-recognized heterogeneity in plasma TG response to n-3 PUFA supplementation. Previous studies have shown that genes in the glycerophospholipid metabolism such as phospholipase A₂ (PLA₂) group II, IV, and VI, demonstrate changes in their expression levels in peripheral blood mononuclear cells (PBMCs) after n-3 PUFA supplementation.

Methods

A total of 208 subjects consumed 3 g/day of n-3 PUFA for 6 weeks. Plasma lipids were measured before and after the supplementation period. Five SNPs in PLA2G2A, six in PLA2G2C, eight in PLA2G2D, six in PLA2G2F, 22 in PLA2G4A, five in PLA2G6, and nine in PLA2G7 were genotyped. The MIXED Procedure for repeated measures adjusted for age, sex, BMI, and energy intake was used in order to test whether the genotype, supplementation or interaction (genotype by supplementation) were associated with plasma TG levels.

Results

The n-3 PUFA supplementation had an independent effect on plasma TG levels. Genotype effects on plasma TG levels were observed for rs2301475 in PLA2G2C, rs818571 in PLA2G2F, and rs1569480 in PLA2G4A. Genotype x supplementation interaction effects on plasma TG levels were observed for rs1805018 in PLA2G7 as well as for rs10752979, rs10737277, rs7540602, and rs3820185 in PLA2G4A.

Conclusion

These results suggest that, SNPs in PLA₂ genes may influence plasma TG levels during a supplementation with n-3 PUFA. This trial was registered at clinicaltrials.gov as NCT01343342.

【 授权许可】

   
2015 Tremblay et al.; licensee BioMed Central .

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]World Health Organization: Global Status Report on Noncommunicable Diseases. WHO Library Cataloguing-in-Publication Data, Geneva; 2011.
• [2]Cullen P: Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 2000, 86:943-9.
• [3]Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, et al.: n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr 2006, 84:5-17.
• [4]Harris WS: n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 1997, 65:1645S-54.
• [5]Kris-Etherton PM, Harris WS, Appel LJ: Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler Thromb Vasc Biol 2003, 23:e20-30.
• [6]Kris-Etherton PM, Innis S, Ammerican DA: Dietitians of Canada: Position of the American dietetic association and dietitians of Canada: dietary fatty acids. J Am Diet Assoc 2007, 107:1599-611.
• [7]McGuire S: U.S. Department of Agriculture and U.S. Department of Health and Human Services, Dietary Guidelines for Americans, 2010. 7th Edition, Washington, DC: U.S. Government Printing Office, January 2011. Adv Nutr 2011, 2:293-294.
• [8]National Health and Medical Research Council. Nutrient Reference Values for Australia and New Zealand Including Recommended Dietary Intakes. Edited by NHMRC. 2005. Canberra.
• [9]Madden J, Williams CM, Calder PC, Lietz G, Miles EA, Cordell H, et al.: The impact of common gene variants on the response of biomarkers of cardiovascular disease (CVD) risk to increased fish oil fatty acids intakes. Annu Rev Nutr 2011, 31:203-34.
• [10]Caslake MJ, Miles EA, Kofler BM, Lietz G, Curtis P, Armah CK, et al.: Effect of sex and genotype on cardiovascular biomarker response to fish oils: the FINGEN Study. Am J Clin Nutr 2008, 88:618-29.
• [11]Masson LF, McNeill G, Avenell A: Genetic variation and the lipid response to dietary intervention: a systematic review. Am J Clin Nutr 2003, 77:1098-111.
• [12]Minihane AM: Fatty acid-genotype interactions and cardiovascular risk. Prostaglandins Leukot Essent Fatty Acids 2010, 82:259-64.
• [13]Rudkowska I, Paradis AM, Thifault E, Julien P, Barbier O, Couture P, et al.: Differences in metabolomic and transcriptomic profiles between responders and non-responders to an n-3 polyunsaturated fatty acids (PUFAs) supplementation. Genes Nutr 2013, 8:411-23.
• [14]Hui DY: Phospholipase A(2) enzymes in metabolic and cardiovascular diseases. Curr Opin Lipidol 2012, 23:235-40.
• [15]Pratico D: Prostanoid and isoprostanoid pathways in atherogenesis. Atherosclerosis 2008, 201:8-16.
• [16]Deigner HP, Hermetter A: Oxidized phospholipids: emerging lipid mediators in pathophysiology. Curr Opin Lipidol 2008, 19:289-94.
• [17]Wymann MP, Schneiter R: Lipid signalling in disease. Nat Rev Mol Cell Biol 2008, 9:162-76.
• [18]Das UN: Can endogenous lipid molecules serve as predictors and prognostic markers of coronary heart disease? Lipids Health Dis 2008, 7:19. BioMed Central Full Text
• [19]Shimizu T: Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol 2009, 49:123-50.
• [20]Cedars A, Jenkins CM, Mancuso DJ, Gross RW: Calcium-independent phospholipases in the heart: mediators of cellular signaling, bioenergetics, and ischemia-induced electrophysiologic dysfunction. J Cardiovasc Pharmacol 2009, 53:277-89.
• [21]Dennis EA, Cao J, Hsu YH, Magrioti V, Kokotos G: Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev 2011, 111:6130-85.
• [22]Kugiyama K, Ota Y, Takazoe K, Moriyama Y, Kawano H, Miyao Y, et al.: Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation 1999, 100:1280-4.
• [23]Mallat Z, Steg PG, Benessiano J, Tanguy ML, Fox KA, Collet JP, et al.: Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol 2005, 46:1249-57.
• [24]Hartiala J, Li D, Conti DV, Vikman S, Patel Y, Tang WH, et al.: Genetic contribution of the leukotriene pathway to coronary artery disease. Hum Genet 2011, 129:617-27.
• [25]Callaway CW, Chumlea WC, Bouchard C, Himes JH, Lohman TG, Martin AD, et al.: Standardization of Anthropomeric Measurements : The Airlie (VA) Consensus Conference. Human Kinetics Publishers, Champaign, IR, USA; 1988.
• [26]McNamara JR, Schaefer EJ: Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta 1987, 166:1-8.
• [27]Albers JJ, Warnick GR, Wiebe D, King P, Steiner P, Smith L, et al.: Multi-laboratory comparison of three heparin-Mn2+ precipitation procedures for estimating cholesterol in high-density lipoprotein. Clin Chem 1978, 24:853-6.
• [28]Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
• [29]Laurell CB: Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966, 15:45-52.
• [30]Pirro M, Bergeron J, Dagenais GR, Bernard PM, Cantin B, Despres JP, et al.: Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men. Arch Intern Med 2001, 161:2474-80.
• [31]Shaikh NA, Downar E: Time course of changes in porcine myocardial phospholipid levels during ischemia. A reassessment of the lysolipid hypothesis. Circ Res 1981, 49:316-25.
• [32]Kroger E, Verreault R, Carmichael PH, Lindsay J, Julien P, Dewailly E, et al.: Omega-3 fatty acids and risk of dementia: the Canadian study of health and aging. Am J Clin Nutr 2009, 90:184-92.
• [33]Livak KJ. Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal. 1999;14:143–9.
• [34]Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, et al.: Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011, 123:2292-333.
• [35]Cormier H, Rudkowska I, Paradis AM, Thifault E, Garneau V, Lemieux S, et al.: Association between polymorphisms in the fatty acid desaturase gene cluster and the plasma triacylglycerol response to an n-3 PUFA supplementation. Nutrients 2012, 4:1026-41.
• [36]Vittos O, Toana B, Vittos A, Moldoveanu E: Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker. Biomarkers 2012, 17:289-302.
• [37]Sertic J, Skoric B, Lovric J, Bozina T, Reiner Z: Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease? Acta Med Croatica 2010, 64:237-45.
• [38]Thifault E, Cormier H, Bouchard-Mercier A, Rudkowska I, Paradis AM, Garneau V, et al.: Effects of age, sex, body mass index and APOE genotype on cardiovascular biomarker response to an n-3 polyunsaturated fatty acid supplementation. J Nutrigenet Nutrigenomics 2013, 6:73-82.
• [39]Tischfield JA, Xia YR, Shih DM, Klisak I, Chen J, Engle SJ, et al.: Low-molecular-weight, calcium-dependent phospholipase A2 genes are linked and map to homologous chromosome regions in mouse and human. Genomics 1996, 32:328-33.
• [40]Sato H, Kato R, Isogai Y, Saka G, Ohtsuki M, Taketomi Y, et al.: Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis. J Biol Chem 2008, 283:33483-97.
• [41]Kimura-Matsumoto M, Ishikawa Y, Komiyama K, Tsuruta T, Murakami M, Masuda S, et al.: Expression of secretory phospholipase A2s in human atherosclerosis development. Atherosclerosis 2008, 196:81-91.
• [42]Liu X, Zhu RX, Tian YL, Li Q, Li L, Deng SM, et al.: Association of PLA2G7 gene polymorphisms with ischemic stroke in northern Chinese Han population. Clin Biochem 2014, 47:404-8.
• [43]Grallert H, Dupuis J, Bis JC, Dehghan A, Barbalic M, Baumert J, et al.: Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies. Eur Heart J 2012, 33:238-51.
• [44]Sutton BS, Crosslin DR, Shah SH, Nelson SC, Bassil A, Hale AB, et al.: Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case–control and family datasets. Hum Mol Genet 2008, 17:1318-28.
• [45]Jang Y, Kim OY, Koh SJ, Chae JS, Ko YG, Kim JY, et al.: The Val279Phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men. J Clin Endocrinol Metab 2006, 91:3521-7.
• [46]Ninio E, Tregouet D, Carrier JL, Stengel D, Bickel C, Perret C, et al.: Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum Mol Genet 2004, 13:1341-51.
• [47]Casas JP, Ninio E, Panayiotou A, Palmen J, Cooper JA, Ricketts SL, et al.: PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. Circulation 2010, 121:2284-93.
• [48]Hou L, Chen S, Yu H, Lu X, Chen J, Wang L, et al.: Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study. Hum Genet 2009, 125:11-20.
• [49]Rapoport SI: Translational studies on regulation of brain docosahexaenoic acid (DHA) metabolism in vivo. Prostaglandins Leukot Essent Fatty Acids 2013, 88:79-85.
• [50]Cheon Y, Kim HW, Igarashi M, Modi HR, Chang L, Ma K, et al.: Disturbed brain phospholipid and docosahexaenoic acid metabolism in calcium-independent phospholipase A(2)-VIA (iPLA(2)beta)-knockout mice. Biochim Biophys Acta 1821, 2012:1278-86.
• [51]Denys A, Hichami A, Khan NA: n-3 PUFAs modulate T-cell activation via protein kinase C-alpha and -epsilon and the NF-kappaB signaling pathway. J Lipid Res 2005, 46:752-8.
• [52]Han C, Demetris AJ, Michalopoulos G, Shelhamer JH, Wu T: 85-kDa cPLA(2) plays a critical role in PPAR-mediated gene transcription in human hepatoma cells. Am J Physiol Gastrointest Liver Physiol 2002, 282:G586-97.
• [53]Pawliczak R, Han C, Huang XL, Demetris AJ, Shelhamer JH, Wu T: 85-kDa cytosolic phospholipase A2 mediates peroxisome proliferator-activated receptor gamma activation in human lung epithelial cells. J Biol Chem 2002, 277:33153-63.
• [54]Calder PC: Mechanisms of action of (n-3) fatty acids. J Nutr 2012, 142:592S-9.
• [55]Chaudhuri A, Rosenstock J, DiGenio A, Meneghini L, Hollander P, McGill JB, et al.: Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis. Diabetes Metab Res Rev 2012, 28:258-67.
• [56]Kong AP, Yamasaki A, Ozaki R, Saito H, Asami T, Ohwada S, et al.: A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab 2011, 13:806-13.